Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP,General Counsel, Secretary | January 06, 2024 | January 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date January 06, 2024 · Filed January 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,901 |
Ending reported balance
After 2024-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-06 · Exercise / conversion · Acquired 1,634 · Balance 47,491 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Row 2 · 2024-01-08 · Sale · Disposed 590 · Balance 46,901 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-06 · Exercise / conversion · Disposed 1,634 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2024 Filed Jan 9, 2024 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 590 | $29.96 | $17,676.40 |
DisclosureSEC source: 0001209191-24-001267 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,901 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.6641 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001267 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,634 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,634 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001267 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| October 06, 2023 Filed Oct 7, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 16,369 | $21.96 | $359,463.24 |
DisclosureSEC source: 0001209191-23-052390 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,857 F3 · price: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 05, 2023 Filed Oct 7, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 36,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052390 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,289 Underlying: Common Stock · 36,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| October 05, 2023 Filed Oct 7, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 36,174 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052390 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · balance_after: Includes 539 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| May 01, 2023 Filed May 2, 2023 23:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 917 | $21.18 | $19,422.06 |
DisclosureSEC source: 0001209191-23-026746 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,513 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:14 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 18,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027204 · doc4.xml · derivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,172 Underlying: Common Stock · 18,172 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:14 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 59,957 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-23-027204 · doc4.xml · derivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,957 Underlying: Common Stock · 59,957 shares Expires 2033-05-01 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 29, 2023 Filed May 2, 2023 23:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026746 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2023 Filed May 2, 2023 23:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026746 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| April 06, 2023 Filed Apr 8, 2023 00:32 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,456 | $18.16 | $26,440.96 |
DisclosureSEC source: 0001209191-23-023861 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,425 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:32 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 4,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023861 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,319 Underlying: Common Stock · 4,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:32 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 4,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023861 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 803 | $18.78 | $15,080.34 |
DisclosureSEC source: 0001209191-23-013469 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,108 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013469 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,428 Underlying: Common Stock · 2,214 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013469 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 01:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 589 | $17.13 | $10,089.75 |
DisclosureSEC source: 0001209191-23-002894 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,697 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 01:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002894 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634 Underlying: Common Stock · 1,633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 01:20 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-002894 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · balance_after: Includes 911 shares of the Issuer's common stock acquired by the reporting person on May 16, 2022 pursuant to an employee stock purchase program. Read SEC document |
| May 02, 2022 Filed May 4, 2022 00:51 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 894 | $18.18 | $16,254.71 |
DisclosureSEC source: 0001209191-22-026938 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,742 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.425, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:51 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026938 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:51 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-026938 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:47 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 96,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023740 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,463 Underlying: Common Stock · 96,463 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:47 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 19,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023740 · doc4.xml · derivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,092 Underlying: Common Stock · 19,092 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:47 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 65,517 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001209191-22-023740 · doc4.xml · derivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP,General Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,517 Underlying: Common Stock · 65,517 shares Expires 2032-04-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013277 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,642 Underlying: Common Stock · 2,213 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 782 | $23.80 | $18,611.60 |
DisclosureSEC source: 0001209191-22-013277 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,631 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:42 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013277 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002750 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,267 Underlying: Common Stock · 1,633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 574 | $23.05 | $13,230.70 |
DisclosureSEC source: 0001209191-22-002750 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:24 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002750 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 365 shares of the Issuer's common stock acquired by the reporting person on May 15, 2021 and 405 shares acquired by the reporting person on November 15, 2021, pursuant to an employee stock purchase program. Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,054 | $20.33 | $21,427.82 |
DisclosureSEC source: 0001209191-21-029358 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,371 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029358 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,010 Underlying: Common Stock · 3,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:54 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029358 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F2 · balance_after: The amount of securities beneficially owned reported in Column 5 above has been adjusted to correct an error in the Reporting Person's prior Form 4 caused by the failure to carry over the correct number of shares from the prior report. The number of shares owned prior to the transactions reported herein was 9,420 shares. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 8,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014558 · doc4.xml · derivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Underlying: Common Stock · 8,855 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:46 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 32,608 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001209191-21-014558 · doc4.xml · derivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,608 Underlying: Common Stock · 32,608 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,107 | $50.61 | $106,635.27 |
DisclosureSEC source: 0001209191-21-008658 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,911 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 6,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008658 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,018 F1 · kind: On April 29, 2019, the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002834 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 1,633 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 678 | $53.34 | $36,164.52 |
DisclosureSEC source: 0001209191-21-002834 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002834 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 712 shares of the Issuer's common stock acquired by the reporting person on November 13, 2020 pursuant to an employee stock purchase program. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 20:12 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001209191-20-056219 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,750 Underlying: Common Stock · 8,750 shares Expires 2028-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on July 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 20:12 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 8,750 | $45.10 | $394,636.38 |
DisclosureSEC source: 0001209191-20-056219 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,851 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 9/18/2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.525, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 20:12 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,750 | $17.58 | $153,825.00 |
DisclosureSEC source: 0001209191-20-056219 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,410 shares of the Issuer's common stock acquired by the reporting person on May 15, 2020 pursuant to an employee stock purchase program. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 1,072 | $49.22 | $52,763.84 |
DisclosureSEC source: 0001209191-20-026619 · doc4.xml · nonDerivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,441 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 29, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 3,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-026619 · doc4.xml · derivative · entry 3 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,015 Underlying: Common Stock · 3,004 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2020 Filed May 1, 2020 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 3,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-026619 · doc4.xml · nonDerivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 6,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002600 · doc4.xml · derivative · entry 2 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,533 Underlying: Common Stock · 6,533 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 23:06 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 23,709 | $0.00 Strike: $42.81 | $0.00 |
DisclosureSEC source: 0001209191-20-002600 · doc4.xml · derivative · entry 1 KIM AUSTIN D. · CIK 0001746240 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,709 Underlying: Common Stock · 23,709 shares Expires 2030-01-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 6, 2021. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.